Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

Regeneron left the American Society for Hematology meeting in San Diego this week with a pair of trial aces, notching a head-to-head win against a rare disease blockbuster and a potential best-in-class performance in the crowded lymphoma market.